Comments on "Electric current and electric field induced in a human body when exposed to an incident electric field near the resonant frequency" [with reply]
For original paper see ibid., vol. 48, no. 9, p. 147-53 (2000). The author makes two observations on the original article. The commentator questions whether a seated person is well modeled as a right circular cylinder. The second observation is that King cites only microwave studies on mice to show that electromagnetic radiation causes malignancies. These studies themselves are widely disputed. He then uses simple dimensional scaling to show that 2.45 GHz for a mouse scales to 100 MHz for a man. Such a scaling law may be useful in calculating the resonant frequency for a human subject versus a mouse when treated as antennas, but such scaling is meaningless when the physics of a hypothetical carcinogenic process are unknown.
Electric current and electric field induced in the human body when exposed to an incident electric field near the resonant frequency
The electric field and current density induced in the human body when this is exposed to electric fields near the resonant frequency, 53 MHz, are determined analytically. Since this frequency range includes an important amateur radio band of 50-60 MHz and exposure to electric fields at this frequency has been shown to be hazardous, the study has a specific motivation. A cylindrical model of the body is used to derive formulas for the total axial current and current density induced in the body subject to skin effect. Tabulations and graphical representations illuminate the results.
Multiple-dose pharmacokinetics of moxisylyte after oral administration to healthy volunteers.
The pharmacokinetics of moxisylyte in plasma and urine was investigated after oral administration. Twelve subjects were treated orally, twice daily with 240 mg of the drug for 6 days; on day 7, the subjects received a last dose of 240 mg of moxisylyte. Moxisylyte was assayed in plasma and urine by a specific HPLC method with fluorimetric detection. Moxisylyte was absorbed rapidly and changed to its metabolites immediately after drug administration; unchanged moxisylyte was not found in plasma. Two metabolites were found in plasma and urine: conjugated desacetylmoxisylyte (DAM) and the conjugate of desmethylated DAM (MDAM). The pharmacokinetic parameters determined after the first oral administration were not modified on multiple dosing. The apparent elimination half-lives of conjugated DAM and MDAM were 2.3 and 3.5 h, respectively. Elimination of these two metabolites in urine averaged 50 and 10%, respectively.